nivolumab,sintilimab
eli lilly,bms
['sintilimab', 'nsclc', 'sclc', 'cm816']
#asco22
ph ii neoscore trial of 2 v 3 cycles of neoadjuvant sintilimab+chemo in nsclc: - mpr higher with 3 v 2 cycles
- higher rates of mpr in squam v non squam nsclc (diff to cm816) an addition to expanding data on neoadjuvant io in early stage nsclc 
Thoracic Oncologist focused on immunotherapy for lung cancer & immune toxicity. Beaumont RCSI Cancer Centre Dublin; Adjunct Asst Prof Johns Hopkins University